Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:absorption |
gptkb:small_intestine
|
| gptkbp:approvedBy |
omeprazole in 1988
|
| gptkbp:ATCCode |
gptkb:A02BC
|
| gptkbp:bioavailability |
varies by drug
|
| gptkbp:category |
gastrointestinal agent
acid suppressant |
| gptkbp:chemicalClass |
substituted benzimidazoles
|
| gptkbp:contraindication |
known hypersensitivity
|
| gptkbp:discoveredIn |
1970s
|
| gptkbp:drugInteraction |
gptkb:warfarin
gptkb:clopidogrel gptkb:methotrexate |
| gptkbp:effect |
reduce stomach acid production
|
| gptkbp:eliminationHalfLife |
1-2 hours
|
| gptkbp:example |
gptkb:omeprazole
gptkb:pantoprazole gptkb:lansoprazole gptkb:rabeprazole gptkb:dexlansoprazole esomeprazole |
| gptkbp:form |
capsule
oral suspension intravenous injection delayed-release tablet |
| gptkbp:legalStatus |
prescription
over-the-counter (some drugs) |
| gptkbp:mechanismOfAction |
inhibit gastric H+/K+ ATPase
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
varies by drug
|
| gptkbp:riskFactor |
gptkb:pneumonia
chronic kidney disease vitamin B12 deficiency gastric cancer (long-term use, debated) |
| gptkbp:routeOfAdministration |
oral
intravenous |
| gptkbp:sideEffect |
nausea
diarrhea abdominal pain headache hypomagnesemia increased risk of Clostridioides difficile infection osteoporosis-related fractures |
| gptkbp:usedFor |
treatment of peptic ulcer disease
treatment of Zollinger-Ellison syndrome treatment of gastroesophageal reflux disease |
| gptkbp:WHOModelListOfEssentialMedicines |
gptkb:omeprazole
|
| gptkbp:bfsParent |
gptkb:Cushing_ulcer
|
| gptkbp:bfsLayer |
6
|
| https://www.w3.org/2000/01/rdf-schema#label |
proton pump inhibitors
|